Global MET Inhibitor Drugs Market
Global MET Inhibitor Drugs Market

MET Inhibitor Drugs Comprehensive Study by Type (C-Met Biological Inhibitors, Small Molecule C-Met Inhibitors, C-Met Antagonist Antibodies, HGF Antagonist Antibodies, Kringle Variant Antagonists), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Stores), End-user (Hospitals, Clinics, Others) Players and Region - Global Market Outlook to 2026

MET Inhibitor Drugs Market Segmented into XX Submarkets. | Forecast Years: 2021- 2026  

Apr 2021 Edition 230 Pages 216 Tables & Figures
  • Summary
  • Market Segments
  • Table of Content
  • List of Tables & Figures
  • Companies Mentioned
What is MET Inhibitor Drugs?
MET inhibitor drugs are the group of drugs that inhibits the mutated forms of the MET gene that may cause abnormal cell growth and spread in the body. These drugs are primarily used for the treatment of different types of cancers such as breast, colon, and lung cancers. According to World Health Organization (WHO), cancer is the second leading cause of death globally and is responsible for about 10 million deaths per year. The factors such as the Increased Prevalence of Cancers among People Worldwide and High Demand for Alternative Treatments for Cancers are the drivers for the global MET Inhibitor Drugs market. In addition, Increased Research and Development Funding also fueling the market growth. However, Limitations Associated with MET Inhibitor Drugs may hinder the market growth.

The market study is broken down by Type (C-Met Biological Inhibitors, Small Molecule C-Met Inhibitors, C-Met Antagonist Antibodies, HGF Antagonist Antibodies and Kringle Variant Antagonists) and major geographies with country level break-up.

The companies are exploring the market by adopting expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions across the globe to gain a competitive advantage through combined collaborations. Research Analyst at AMA estimates that Players from United States will contribute to the maximum growth of Global MET Inhibitor Drugs market throughout the predicted period.

Abbott Laboratories (United States), Johnson and Johnson (United States), Novartis International AG (Switzerland), Eli Lilly and Company (United States), Pfizer Inc. (United States), Merck & Co., Inc. (United States), Takeda Pharmaceutical Company (Japan), GlaxoSmithKline plc (United Kingdom), Amgen Inc. (United States), Bristol Myers Squibb (United States) and Daiichi Sankyo Company, Limited (Japan) are some of the key players that are part of study coverage.

Segmentation Overview
AdvanceMarketAnalytics has segmented the market of Global MET Inhibitor Drugs market by Type, Application and Region.

On the basis of geography, the market of MET Inhibitor Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Distribution Channel, the sub-segment i.e. Hospital Pharmacies will boost the MET Inhibitor Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by End-user, the sub-segment i.e. Hospitals will boost the MET Inhibitor Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

In May 2020, Novartis announced that the United States Food and Drug Administration (FDA) has approved Tabrecta (capmatinib, formerly INC280), an oral MET inhibitor for adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test.


Market Trend
  • Increased Research and Development Funding

Market Drivers
  • Increased Prevalence of Cancer among People Worldwide
  • High Demand for Alternative Treatments for Cancers
  • Growth in the Healthcare Infrastructure in Developing Countries

Opportunities
  • Growth in the Healthcare Industry
  • Huge Investments by Major Players

Restraints
  • Limitations Associated with MET Inhibitor Drugs

Challenges
  • Stringent Government Rules and Regulations


Key Target Audience
MET Inhibitor Drugs Manufacturers, Distributors, Emerging Companies, Research Professionals and End-users

About Approach
During this study the evaluation and validation of the market size is done through various sources including primary and secondary analysis. AMA Research & Media follows industrial and regulatory standards such as NAICS/SIC/ICB/TRCB, to have the better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with purpose to understand company’s positioning regarding market value, volume and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders etc. and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, analyst team keeps preparing set of questionnaires and after getting appointee list; the target audience are then tapped and segregated with various mediums and channels that are feasible for making connection that includes email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey etc.

Customization available in this Study:
The Study can be customized to meet your requirements. Please connect with our representative, who will ensure you get a report that suits your needs.
Data related to EXIM [Export- Import], production & consumption by country or regional level break-up can be provided based on client request**
** Confirmation on availability of data would be informed prior purchase
Report Objectives / Segmentation Covered
By Type
  • C-Met Biological Inhibitors
  • Small Molecule C-Met Inhibitors
  • C-Met Antagonist Antibodies
  • HGF Antagonist Antibodies
  • Kringle Variant Antagonists
By Distribution Channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Drug Stores
  • Online Stores

By End-user
  • Hospitals
  • Clinics
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increased Prevalence of Cancer among People Worldwide
      • 3.2.2. High Demand for Alternative Treatments for Cancers
      • 3.2.3. Growth in the Healthcare Infrastructure in Developing Countries
    • 3.3. Market Challenges
      • 3.3.1. Stringent Government Rules and Regulations
    • 3.4. Market Trends
      • 3.4.1. Increased Research and Development Funding
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global MET Inhibitor Drugs, by Type, Distribution Channel, End-user and Region (value, volume and price ) (2015-2020)
    • 5.1. Introduction
    • 5.2. Global MET Inhibitor Drugs (Value)
      • 5.2.1. Global MET Inhibitor Drugs by: Type (Value)
        • 5.2.1.1. C-Met Biological Inhibitors
        • 5.2.1.2. Small Molecule C-Met Inhibitors
        • 5.2.1.3. C-Met Antagonist Antibodies
        • 5.2.1.4. HGF Antagonist Antibodies
        • 5.2.1.5. Kringle Variant Antagonists
      • 5.2.2. Global MET Inhibitor Drugs by: Distribution Channel (Value)
        • 5.2.2.1. Hospital Pharmacies
        • 5.2.2.2. Retail Pharmacies
        • 5.2.2.3. Drug Stores
        • 5.2.2.4. Online Stores
      • 5.2.3. Global MET Inhibitor Drugs by: End-user (Value)
        • 5.2.3.1. Hospitals
        • 5.2.3.2. Clinics
        • 5.2.3.3. Others
      • 5.2.4. Global MET Inhibitor Drugs Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
    • 5.3. Global MET Inhibitor Drugs (Volume)
      • 5.3.1. Global MET Inhibitor Drugs by: Type (Volume)
        • 5.3.1.1. C-Met Biological Inhibitors
        • 5.3.1.2. Small Molecule C-Met Inhibitors
        • 5.3.1.3. C-Met Antagonist Antibodies
        • 5.3.1.4. HGF Antagonist Antibodies
        • 5.3.1.5. Kringle Variant Antagonists
      • 5.3.2. Global MET Inhibitor Drugs by: Distribution Channel (Volume)
        • 5.3.2.1. Hospital Pharmacies
        • 5.3.2.2. Retail Pharmacies
        • 5.3.2.3. Drug Stores
        • 5.3.2.4. Online Stores
      • 5.3.3. Global MET Inhibitor Drugs by: End-user (Volume)
        • 5.3.3.1. Hospitals
        • 5.3.3.2. Clinics
        • 5.3.3.3. Others
      • 5.3.4. Global MET Inhibitor Drugs Region
        • 5.3.4.1. South America
          • 5.3.4.1.1. Brazil
          • 5.3.4.1.2. Argentina
          • 5.3.4.1.3. Rest of South America
        • 5.3.4.2. Asia Pacific
          • 5.3.4.2.1. China
          • 5.3.4.2.2. Japan
          • 5.3.4.2.3. India
          • 5.3.4.2.4. South Korea
          • 5.3.4.2.5. Taiwan
          • 5.3.4.2.6. Australia
          • 5.3.4.2.7. Rest of Asia-Pacific
        • 5.3.4.3. Europe
          • 5.3.4.3.1. Germany
          • 5.3.4.3.2. France
          • 5.3.4.3.3. Italy
          • 5.3.4.3.4. United Kingdom
          • 5.3.4.3.5. Netherlands
          • 5.3.4.3.6. Rest of Europe
        • 5.3.4.4. MEA
          • 5.3.4.4.1. Middle East
          • 5.3.4.4.2. Africa
        • 5.3.4.5. North America
          • 5.3.4.5.1. United States
          • 5.3.4.5.2. Canada
          • 5.3.4.5.3. Mexico
    • 5.4. Global MET Inhibitor Drugs (Price)
      • 5.4.1. Global MET Inhibitor Drugs by: Type (Price)
  • 6. MET Inhibitor Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2020)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Abbott Laboratories (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Johnson and Johnson (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Novartis International AG (Switzerland)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Eli Lilly and Company (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer Inc. (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Merck & Co., Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Takeda Pharmaceutical Company (Japan)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. GlaxoSmithKline plc (United Kingdom)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Amgen Inc. (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Bristol Myers Squibb (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Daiichi Sankyo Company, Limited (Japan)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
  • 7. Global MET Inhibitor Drugs Sale, by Type, Distribution Channel, End-user and Region (value, volume and price ) (2021-2026)
    • 7.1. Introduction
    • 7.2. Global MET Inhibitor Drugs (Value)
      • 7.2.1. Global MET Inhibitor Drugs by: Type (Value)
        • 7.2.1.1. C-Met Biological Inhibitors
        • 7.2.1.2. Small Molecule C-Met Inhibitors
        • 7.2.1.3. C-Met Antagonist Antibodies
        • 7.2.1.4. HGF Antagonist Antibodies
        • 7.2.1.5. Kringle Variant Antagonists
      • 7.2.2. Global MET Inhibitor Drugs by: Distribution Channel (Value)
        • 7.2.2.1. Hospital Pharmacies
        • 7.2.2.2. Retail Pharmacies
        • 7.2.2.3. Drug Stores
        • 7.2.2.4. Online Stores
      • 7.2.3. Global MET Inhibitor Drugs by: End-user (Value)
        • 7.2.3.1. Hospitals
        • 7.2.3.2. Clinics
        • 7.2.3.3. Others
      • 7.2.4. Global MET Inhibitor Drugs Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
    • 7.3. Global MET Inhibitor Drugs (Volume)
      • 7.3.1. Global MET Inhibitor Drugs by: Type (Volume)
        • 7.3.1.1. C-Met Biological Inhibitors
        • 7.3.1.2. Small Molecule C-Met Inhibitors
        • 7.3.1.3. C-Met Antagonist Antibodies
        • 7.3.1.4. HGF Antagonist Antibodies
        • 7.3.1.5. Kringle Variant Antagonists
      • 7.3.2. Global MET Inhibitor Drugs by: Distribution Channel (Volume)
        • 7.3.2.1. Hospital Pharmacies
        • 7.3.2.2. Retail Pharmacies
        • 7.3.2.3. Drug Stores
        • 7.3.2.4. Online Stores
      • 7.3.3. Global MET Inhibitor Drugs by: End-user (Volume)
        • 7.3.3.1. Hospitals
        • 7.3.3.2. Clinics
        • 7.3.3.3. Others
      • 7.3.4. Global MET Inhibitor Drugs Region
        • 7.3.4.1. South America
          • 7.3.4.1.1. Brazil
          • 7.3.4.1.2. Argentina
          • 7.3.4.1.3. Rest of South America
        • 7.3.4.2. Asia Pacific
          • 7.3.4.2.1. China
          • 7.3.4.2.2. Japan
          • 7.3.4.2.3. India
          • 7.3.4.2.4. South Korea
          • 7.3.4.2.5. Taiwan
          • 7.3.4.2.6. Australia
          • 7.3.4.2.7. Rest of Asia-Pacific
        • 7.3.4.3. Europe
          • 7.3.4.3.1. Germany
          • 7.3.4.3.2. France
          • 7.3.4.3.3. Italy
          • 7.3.4.3.4. United Kingdom
          • 7.3.4.3.5. Netherlands
          • 7.3.4.3.6. Rest of Europe
        • 7.3.4.4. MEA
          • 7.3.4.4.1. Middle East
          • 7.3.4.4.2. Africa
        • 7.3.4.5. North America
          • 7.3.4.5.1. United States
          • 7.3.4.5.2. Canada
          • 7.3.4.5.3. Mexico
    • 7.4. Global MET Inhibitor Drugs (Price)
      • 7.4.1. Global MET Inhibitor Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. MET Inhibitor Drugs: by Type(USD Million)
  • Table 2. MET Inhibitor Drugs C-Met Biological Inhibitors , by Region USD Million (2015-2020)
  • Table 3. MET Inhibitor Drugs Small Molecule C-Met Inhibitors , by Region USD Million (2015-2020)
  • Table 4. MET Inhibitor Drugs C-Met Antagonist Antibodies , by Region USD Million (2015-2020)
  • Table 5. MET Inhibitor Drugs HGF Antagonist Antibodies , by Region USD Million (2015-2020)
  • Table 6. MET Inhibitor Drugs Kringle Variant Antagonists , by Region USD Million (2015-2020)
  • Table 7. MET Inhibitor Drugs: by Distribution Channel(USD Million)
  • Table 8. MET Inhibitor Drugs Hospital Pharmacies , by Region USD Million (2015-2020)
  • Table 9. MET Inhibitor Drugs Retail Pharmacies , by Region USD Million (2015-2020)
  • Table 10. MET Inhibitor Drugs Drug Stores , by Region USD Million (2015-2020)
  • Table 11. MET Inhibitor Drugs Online Stores , by Region USD Million (2015-2020)
  • Table 12. MET Inhibitor Drugs: by End-user(USD Million)
  • Table 13. MET Inhibitor Drugs Hospitals , by Region USD Million (2015-2020)
  • Table 14. MET Inhibitor Drugs Clinics , by Region USD Million (2015-2020)
  • Table 15. MET Inhibitor Drugs Others , by Region USD Million (2015-2020)
  • Table 16. South America MET Inhibitor Drugs, by Country USD Million (2015-2020)
  • Table 17. South America MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 18. South America MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 19. South America MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 20. Brazil MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 21. Brazil MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 22. Brazil MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 23. Argentina MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 24. Argentina MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 25. Argentina MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 26. Rest of South America MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 27. Rest of South America MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 28. Rest of South America MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 29. Asia Pacific MET Inhibitor Drugs, by Country USD Million (2015-2020)
  • Table 30. Asia Pacific MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 31. Asia Pacific MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 32. Asia Pacific MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 33. China MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 34. China MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 35. China MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 36. Japan MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 37. Japan MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 38. Japan MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 39. India MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 40. India MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 41. India MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 42. South Korea MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 43. South Korea MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 44. South Korea MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 45. Taiwan MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 46. Taiwan MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 47. Taiwan MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 48. Australia MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 49. Australia MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 50. Australia MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 51. Rest of Asia-Pacific MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 52. Rest of Asia-Pacific MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 53. Rest of Asia-Pacific MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 54. Europe MET Inhibitor Drugs, by Country USD Million (2015-2020)
  • Table 55. Europe MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 56. Europe MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 57. Europe MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 58. Germany MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 59. Germany MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 60. Germany MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 61. France MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 62. France MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 63. France MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 64. Italy MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 65. Italy MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 66. Italy MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 67. United Kingdom MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 68. United Kingdom MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 69. United Kingdom MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 70. Netherlands MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 71. Netherlands MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 72. Netherlands MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 73. Rest of Europe MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 74. Rest of Europe MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 75. Rest of Europe MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 76. MEA MET Inhibitor Drugs, by Country USD Million (2015-2020)
  • Table 77. MEA MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 78. MEA MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 79. MEA MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 80. Middle East MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 81. Middle East MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 82. Middle East MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 83. Africa MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 84. Africa MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 85. Africa MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 86. North America MET Inhibitor Drugs, by Country USD Million (2015-2020)
  • Table 87. North America MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 88. North America MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 89. North America MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 90. United States MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 91. United States MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 92. United States MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 93. Canada MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 94. Canada MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 95. Canada MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 96. Mexico MET Inhibitor Drugs, by Type USD Million (2015-2020)
  • Table 97. Mexico MET Inhibitor Drugs, by Distribution Channel USD Million (2015-2020)
  • Table 98. Mexico MET Inhibitor Drugs, by End-user USD Million (2015-2020)
  • Table 99. MET Inhibitor Drugs Sales: by Type(K Units)
  • Table 100. MET Inhibitor Drugs Sales C-Met Biological Inhibitors , by Region K Units (2015-2020)
  • Table 101. MET Inhibitor Drugs Sales Small Molecule C-Met Inhibitors , by Region K Units (2015-2020)
  • Table 102. MET Inhibitor Drugs Sales C-Met Antagonist Antibodies , by Region K Units (2015-2020)
  • Table 103. MET Inhibitor Drugs Sales HGF Antagonist Antibodies , by Region K Units (2015-2020)
  • Table 104. MET Inhibitor Drugs Sales Kringle Variant Antagonists , by Region K Units (2015-2020)
  • Table 105. MET Inhibitor Drugs Sales: by Distribution Channel(K Units)
  • Table 106. MET Inhibitor Drugs Sales Hospital Pharmacies , by Region K Units (2015-2020)
  • Table 107. MET Inhibitor Drugs Sales Retail Pharmacies , by Region K Units (2015-2020)
  • Table 108. MET Inhibitor Drugs Sales Drug Stores , by Region K Units (2015-2020)
  • Table 109. MET Inhibitor Drugs Sales Online Stores , by Region K Units (2015-2020)
  • Table 110. MET Inhibitor Drugs Sales: by End-user(K Units)
  • Table 111. MET Inhibitor Drugs Sales Hospitals , by Region K Units (2015-2020)
  • Table 112. MET Inhibitor Drugs Sales Clinics , by Region K Units (2015-2020)
  • Table 113. MET Inhibitor Drugs Sales Others , by Region K Units (2015-2020)
  • Table 114. South America MET Inhibitor Drugs Sales, by Country K Units (2015-2020)
  • Table 115. South America MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 116. South America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 117. South America MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 118. Brazil MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 119. Brazil MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 120. Brazil MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 121. Argentina MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 122. Argentina MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 123. Argentina MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 124. Rest of South America MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 125. Rest of South America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 126. Rest of South America MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 127. Asia Pacific MET Inhibitor Drugs Sales, by Country K Units (2015-2020)
  • Table 128. Asia Pacific MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 129. Asia Pacific MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 130. Asia Pacific MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 131. China MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 132. China MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 133. China MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 134. Japan MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 135. Japan MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 136. Japan MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 137. India MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 138. India MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 139. India MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 140. South Korea MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 141. South Korea MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 142. South Korea MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 143. Taiwan MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 144. Taiwan MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 145. Taiwan MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 146. Australia MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 147. Australia MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 148. Australia MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 149. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 150. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 151. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 152. Europe MET Inhibitor Drugs Sales, by Country K Units (2015-2020)
  • Table 153. Europe MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 154. Europe MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 155. Europe MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 156. Germany MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 157. Germany MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 158. Germany MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 159. France MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 160. France MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 161. France MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 162. Italy MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 163. Italy MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 164. Italy MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 165. United Kingdom MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 166. United Kingdom MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 167. United Kingdom MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 168. Netherlands MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 169. Netherlands MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 170. Netherlands MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 171. Rest of Europe MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 172. Rest of Europe MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 173. Rest of Europe MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 174. MEA MET Inhibitor Drugs Sales, by Country K Units (2015-2020)
  • Table 175. MEA MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 176. MEA MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 177. MEA MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 178. Middle East MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 179. Middle East MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 180. Middle East MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 181. Africa MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 182. Africa MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 183. Africa MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 184. North America MET Inhibitor Drugs Sales, by Country K Units (2015-2020)
  • Table 185. North America MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 186. North America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 187. North America MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 188. United States MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 189. United States MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 190. United States MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 191. Canada MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 192. Canada MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 193. Canada MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 194. Mexico MET Inhibitor Drugs Sales, by Type K Units (2015-2020)
  • Table 195. Mexico MET Inhibitor Drugs Sales, by Distribution Channel K Units (2015-2020)
  • Table 196. Mexico MET Inhibitor Drugs Sales, by End-user K Units (2015-2020)
  • Table 197. MET Inhibitor Drugs: by Type(USD/Units)
  • Table 198. Company Basic Information, Sales Area and Its Competitors
  • Table 199. Company Basic Information, Sales Area and Its Competitors
  • Table 200. Company Basic Information, Sales Area and Its Competitors
  • Table 201. Company Basic Information, Sales Area and Its Competitors
  • Table 202. Company Basic Information, Sales Area and Its Competitors
  • Table 203. Company Basic Information, Sales Area and Its Competitors
  • Table 204. Company Basic Information, Sales Area and Its Competitors
  • Table 205. Company Basic Information, Sales Area and Its Competitors
  • Table 206. Company Basic Information, Sales Area and Its Competitors
  • Table 207. Company Basic Information, Sales Area and Its Competitors
  • Table 208. Company Basic Information, Sales Area and Its Competitors
  • Table 209. MET Inhibitor Drugs: by Type(USD Million)
  • Table 210. MET Inhibitor Drugs C-Met Biological Inhibitors , by Region USD Million (2021-2026)
  • Table 211. MET Inhibitor Drugs Small Molecule C-Met Inhibitors , by Region USD Million (2021-2026)
  • Table 212. MET Inhibitor Drugs C-Met Antagonist Antibodies , by Region USD Million (2021-2026)
  • Table 213. MET Inhibitor Drugs HGF Antagonist Antibodies , by Region USD Million (2021-2026)
  • Table 214. MET Inhibitor Drugs Kringle Variant Antagonists , by Region USD Million (2021-2026)
  • Table 215. MET Inhibitor Drugs: by Distribution Channel(USD Million)
  • Table 216. MET Inhibitor Drugs Hospital Pharmacies , by Region USD Million (2021-2026)
  • Table 217. MET Inhibitor Drugs Retail Pharmacies , by Region USD Million (2021-2026)
  • Table 218. MET Inhibitor Drugs Drug Stores , by Region USD Million (2021-2026)
  • Table 219. MET Inhibitor Drugs Online Stores , by Region USD Million (2021-2026)
  • Table 220. MET Inhibitor Drugs: by End-user(USD Million)
  • Table 221. MET Inhibitor Drugs Hospitals , by Region USD Million (2021-2026)
  • Table 222. MET Inhibitor Drugs Clinics , by Region USD Million (2021-2026)
  • Table 223. MET Inhibitor Drugs Others , by Region USD Million (2021-2026)
  • Table 224. South America MET Inhibitor Drugs, by Country USD Million (2021-2026)
  • Table 225. South America MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 226. South America MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 227. South America MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 228. Brazil MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 229. Brazil MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 230. Brazil MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 231. Argentina MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 232. Argentina MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 233. Argentina MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 234. Rest of South America MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 235. Rest of South America MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 236. Rest of South America MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 237. Asia Pacific MET Inhibitor Drugs, by Country USD Million (2021-2026)
  • Table 238. Asia Pacific MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 239. Asia Pacific MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 240. Asia Pacific MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 241. China MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 242. China MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 243. China MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 244. Japan MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 245. Japan MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 246. Japan MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 247. India MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 248. India MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 249. India MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 250. South Korea MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 251. South Korea MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 252. South Korea MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 253. Taiwan MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 254. Taiwan MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 255. Taiwan MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 256. Australia MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 257. Australia MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 258. Australia MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 259. Rest of Asia-Pacific MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 260. Rest of Asia-Pacific MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 261. Rest of Asia-Pacific MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 262. Europe MET Inhibitor Drugs, by Country USD Million (2021-2026)
  • Table 263. Europe MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 264. Europe MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 265. Europe MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 266. Germany MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 267. Germany MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 268. Germany MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 269. France MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 270. France MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 271. France MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 272. Italy MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 273. Italy MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 274. Italy MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 275. United Kingdom MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 276. United Kingdom MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 277. United Kingdom MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 278. Netherlands MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 279. Netherlands MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 280. Netherlands MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 281. Rest of Europe MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 282. Rest of Europe MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 283. Rest of Europe MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 284. MEA MET Inhibitor Drugs, by Country USD Million (2021-2026)
  • Table 285. MEA MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 286. MEA MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 287. MEA MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 288. Middle East MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 289. Middle East MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 290. Middle East MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 291. Africa MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 292. Africa MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 293. Africa MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 294. North America MET Inhibitor Drugs, by Country USD Million (2021-2026)
  • Table 295. North America MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 296. North America MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 297. North America MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 298. United States MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 299. United States MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 300. United States MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 301. Canada MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 302. Canada MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 303. Canada MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 304. Mexico MET Inhibitor Drugs, by Type USD Million (2021-2026)
  • Table 305. Mexico MET Inhibitor Drugs, by Distribution Channel USD Million (2021-2026)
  • Table 306. Mexico MET Inhibitor Drugs, by End-user USD Million (2021-2026)
  • Table 307. MET Inhibitor Drugs Sales: by Type(K Units)
  • Table 308. MET Inhibitor Drugs Sales C-Met Biological Inhibitors , by Region K Units (2021-2026)
  • Table 309. MET Inhibitor Drugs Sales Small Molecule C-Met Inhibitors , by Region K Units (2021-2026)
  • Table 310. MET Inhibitor Drugs Sales C-Met Antagonist Antibodies , by Region K Units (2021-2026)
  • Table 311. MET Inhibitor Drugs Sales HGF Antagonist Antibodies , by Region K Units (2021-2026)
  • Table 312. MET Inhibitor Drugs Sales Kringle Variant Antagonists , by Region K Units (2021-2026)
  • Table 313. MET Inhibitor Drugs Sales: by Distribution Channel(K Units)
  • Table 314. MET Inhibitor Drugs Sales Hospital Pharmacies , by Region K Units (2021-2026)
  • Table 315. MET Inhibitor Drugs Sales Retail Pharmacies , by Region K Units (2021-2026)
  • Table 316. MET Inhibitor Drugs Sales Drug Stores , by Region K Units (2021-2026)
  • Table 317. MET Inhibitor Drugs Sales Online Stores , by Region K Units (2021-2026)
  • Table 318. MET Inhibitor Drugs Sales: by End-user(K Units)
  • Table 319. MET Inhibitor Drugs Sales Hospitals , by Region K Units (2021-2026)
  • Table 320. MET Inhibitor Drugs Sales Clinics , by Region K Units (2021-2026)
  • Table 321. MET Inhibitor Drugs Sales Others , by Region K Units (2021-2026)
  • Table 322. South America MET Inhibitor Drugs Sales, by Country K Units (2021-2026)
  • Table 323. South America MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 324. South America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 325. South America MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 326. Brazil MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 327. Brazil MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 328. Brazil MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 329. Argentina MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 330. Argentina MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 331. Argentina MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 332. Rest of South America MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 333. Rest of South America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 334. Rest of South America MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 335. Asia Pacific MET Inhibitor Drugs Sales, by Country K Units (2021-2026)
  • Table 336. Asia Pacific MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 337. Asia Pacific MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 338. Asia Pacific MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 339. China MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 340. China MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 341. China MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 342. Japan MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 343. Japan MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 344. Japan MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 345. India MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 346. India MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 347. India MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 348. South Korea MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 349. South Korea MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 350. South Korea MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 351. Taiwan MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 352. Taiwan MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 353. Taiwan MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 354. Australia MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 355. Australia MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 356. Australia MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 357. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 358. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 359. Rest of Asia-Pacific MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 360. Europe MET Inhibitor Drugs Sales, by Country K Units (2021-2026)
  • Table 361. Europe MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 362. Europe MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 363. Europe MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 364. Germany MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 365. Germany MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 366. Germany MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 367. France MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 368. France MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 369. France MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 370. Italy MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 371. Italy MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 372. Italy MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 373. United Kingdom MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 374. United Kingdom MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 375. United Kingdom MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 376. Netherlands MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 377. Netherlands MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 378. Netherlands MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 379. Rest of Europe MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 380. Rest of Europe MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 381. Rest of Europe MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 382. MEA MET Inhibitor Drugs Sales, by Country K Units (2021-2026)
  • Table 383. MEA MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 384. MEA MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 385. MEA MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 386. Middle East MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 387. Middle East MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 388. Middle East MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 389. Africa MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 390. Africa MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 391. Africa MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 392. North America MET Inhibitor Drugs Sales, by Country K Units (2021-2026)
  • Table 393. North America MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 394. North America MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 395. North America MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 396. United States MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 397. United States MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 398. United States MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 399. Canada MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 400. Canada MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 401. Canada MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 402. Mexico MET Inhibitor Drugs Sales, by Type K Units (2021-2026)
  • Table 403. Mexico MET Inhibitor Drugs Sales, by Distribution Channel K Units (2021-2026)
  • Table 404. Mexico MET Inhibitor Drugs Sales, by End-user K Units (2021-2026)
  • Table 405. MET Inhibitor Drugs: by Type(USD/Units)
  • Table 406. Research Programs/Design for This Report
  • Table 407. Key Data Information from Secondary Sources
  • Table 408. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global MET Inhibitor Drugs: by Type USD Million (2015-2020)
  • Figure 5. Global MET Inhibitor Drugs: by Distribution Channel USD Million (2015-2020)
  • Figure 6. Global MET Inhibitor Drugs: by End-user USD Million (2015-2020)
  • Figure 7. South America MET Inhibitor Drugs Share (%), by Country
  • Figure 8. Asia Pacific MET Inhibitor Drugs Share (%), by Country
  • Figure 9. Europe MET Inhibitor Drugs Share (%), by Country
  • Figure 10. MEA MET Inhibitor Drugs Share (%), by Country
  • Figure 11. North America MET Inhibitor Drugs Share (%), by Country
  • Figure 12. Global MET Inhibitor Drugs: by Type K Units (2015-2020)
  • Figure 13. Global MET Inhibitor Drugs: by Distribution Channel K Units (2015-2020)
  • Figure 14. Global MET Inhibitor Drugs: by End-user K Units (2015-2020)
  • Figure 15. South America MET Inhibitor Drugs Share (%), by Country
  • Figure 16. Asia Pacific MET Inhibitor Drugs Share (%), by Country
  • Figure 17. Europe MET Inhibitor Drugs Share (%), by Country
  • Figure 18. MEA MET Inhibitor Drugs Share (%), by Country
  • Figure 19. North America MET Inhibitor Drugs Share (%), by Country
  • Figure 20. Global MET Inhibitor Drugs: by Type USD/Units (2015-2020)
  • Figure 21. Global MET Inhibitor Drugs share by Players 2020 (%)
  • Figure 22. Global MET Inhibitor Drugs share by Players (Top 3) 2020(%)
  • Figure 23. Global MET Inhibitor Drugs share by Players (Top 5) 2020(%)
  • Figure 24. BCG Matrix for key Companies
  • Figure 25. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 26. Abbott Laboratories (United States) Revenue: by Geography 2020
  • Figure 27. Johnson and Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 28. Johnson and Johnson (United States) Revenue: by Geography 2020
  • Figure 29. Novartis International AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 30. Novartis International AG (Switzerland) Revenue: by Geography 2020
  • Figure 31. Eli Lilly and Company (United States) Revenue, Net Income and Gross profit
  • Figure 32. Eli Lilly and Company (United States) Revenue: by Geography 2020
  • Figure 33. Pfizer Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 34. Pfizer Inc. (United States) Revenue: by Geography 2020
  • Figure 35. Merck & Co., Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Merck & Co., Inc. (United States) Revenue: by Geography 2020
  • Figure 37. Takeda Pharmaceutical Company (Japan) Revenue, Net Income and Gross profit
  • Figure 38. Takeda Pharmaceutical Company (Japan) Revenue: by Geography 2020
  • Figure 39. GlaxoSmithKline plc (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 40. GlaxoSmithKline plc (United Kingdom) Revenue: by Geography 2020
  • Figure 41. Amgen Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 42. Amgen Inc. (United States) Revenue: by Geography 2020
  • Figure 43. Bristol Myers Squibb (United States) Revenue, Net Income and Gross profit
  • Figure 44. Bristol Myers Squibb (United States) Revenue: by Geography 2020
  • Figure 45. Daiichi Sankyo Company, Limited (Japan) Revenue, Net Income and Gross profit
  • Figure 46. Daiichi Sankyo Company, Limited (Japan) Revenue: by Geography 2020
  • Figure 47. Global MET Inhibitor Drugs: by Type USD Million (2021-2026)
  • Figure 48. Global MET Inhibitor Drugs: by Distribution Channel USD Million (2021-2026)
  • Figure 49. Global MET Inhibitor Drugs: by End-user USD Million (2021-2026)
  • Figure 50. South America MET Inhibitor Drugs Share (%), by Country
  • Figure 51. Asia Pacific MET Inhibitor Drugs Share (%), by Country
  • Figure 52. Europe MET Inhibitor Drugs Share (%), by Country
  • Figure 53. MEA MET Inhibitor Drugs Share (%), by Country
  • Figure 54. North America MET Inhibitor Drugs Share (%), by Country
  • Figure 55. Global MET Inhibitor Drugs: by Type K Units (2021-2026)
  • Figure 56. Global MET Inhibitor Drugs: by Distribution Channel K Units (2021-2026)
  • Figure 57. Global MET Inhibitor Drugs: by End-user K Units (2021-2026)
  • Figure 58. South America MET Inhibitor Drugs Share (%), by Country
  • Figure 59. Asia Pacific MET Inhibitor Drugs Share (%), by Country
  • Figure 60. Europe MET Inhibitor Drugs Share (%), by Country
  • Figure 61. MEA MET Inhibitor Drugs Share (%), by Country
  • Figure 62. North America MET Inhibitor Drugs Share (%), by Country
  • Figure 63. Global MET Inhibitor Drugs: by Type USD/Units (2021-2026)
Some of the key companies/manufacturers profiled in the report
  • Abbott Laboratories (United States)
  • Johnson and Johnson (United States)
  • Novartis International AG (Switzerland)
  • Eli Lilly and Company (United States)
  • Pfizer Inc. (United States)
  • Merck & Co., Inc. (United States)
  • Takeda Pharmaceutical Company (Japan)
  • GlaxoSmithKline plc (United Kingdom)
  • Amgen Inc. (United States)
  • Bristol Myers Squibb (United States)
  • Daiichi Sankyo Company, Limited (Japan)
Select License Type
Sample Report Enquiry Before Buy Request Discount

Speak with Analyst

Want to find out more about this report?

Get Free Consultation